{"cik":2096997,"taxonomy":"us-gaap","tag":"EarningsPerShareBasic","label":"Earnings Per Share, Basic","description":"The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.","entityName":"Kailera Therapeutics, Inc.","units":{"USD/shares":[{"start":"2025-01-01","end":"2025-03-31","val":-17983,"accn":"0001193125-26-239417","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-26","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":-46930,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2025-04-01","end":"2025-06-30","val":-28947,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2025Q2"},{"start":"2026-01-01","end":"2026-03-31","val":-3650,"accn":"0001193125-26-239417","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-26","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":-3.72,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2026-04-01","end":"2026-06-30","val":-1.09,"accn":"0001193125-26-346958","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2"}]}}